Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injection site toleration of VIAject 7, VIAject 25 and insulin lispro in diabetes mellitus
2009-013264-39Phase 3Completed
- Sponsor
- Biodel Inc.
- Start
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of VIAject in diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Biodel Inc. Primary endpoint: Injection site discomfort. Started Jul 2009; status: completed.
02
Drugs
VIAject
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-013264-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013264-39.